Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) CAO Kristen Marie Williams sold 10,000 shares of the business’s stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the transaction, the chief accounting officer now directly owns 23,455 shares in the company, valued at $938,200. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Shares of Pacira Pharmaceuticals, Inc. (NASDAQ PCRX) opened at $44.50 on Thursday. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.99 and a quick ratio of 6.24. Pacira Pharmaceuticals, Inc. has a twelve month low of $29.81 and a twelve month high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.15. The company had revenue of $67.30 million during the quarter, compared to analyst estimates of $68.99 million. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. Pacira Pharmaceuticals’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.20 earnings per share. research analysts predict that Pacira Pharmaceuticals, Inc. will post -0.87 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.watchlistnews.com/insider-selling-pacira-pharmaceuticals-inc-pcrx-cao-sells-400000-00-in-stock/1721487.html.

A number of research analysts recently weighed in on the company. Mizuho reaffirmed a “buy” rating and set a $54.00 price target on shares of Pacira Pharmaceuticals in a research note on Wednesday, July 26th. BidaskClub downgraded Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. BMO Capital Markets upped their price target on Pacira Pharmaceuticals from $38.00 to $39.00 and gave the stock a “market perform” rating in a research note on Wednesday, November 8th. Jefferies Group LLC dropped their price target on Pacira Pharmaceuticals to $52.00 and set a “buy” rating on the stock in a research note on Thursday, November 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $52.00 price target on shares of Pacira Pharmaceuticals in a research note on Thursday, November 9th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $49.71.

Several hedge funds have recently added to or reduced their stakes in PCRX. Principal Financial Group Inc. bought a new position in shares of Pacira Pharmaceuticals in the first quarter valued at approximately $237,000. Teachers Advisors LLC grew its holdings in shares of Pacira Pharmaceuticals by 238.5% in the first quarter. Teachers Advisors LLC now owns 212,792 shares of the company’s stock valued at $9,703,000 after acquiring an additional 149,938 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Pacira Pharmaceuticals by 4.1% in the first quarter. Vanguard Group Inc. now owns 2,860,092 shares of the company’s stock valued at $130,420,000 after acquiring an additional 112,853 shares in the last quarter. UBS Group AG grew its holdings in shares of Pacira Pharmaceuticals by 96.8% in the first quarter. UBS Group AG now owns 14,473 shares of the company’s stock valued at $660,000 after acquiring an additional 7,117 shares in the last quarter. Finally, BlackRock Inc. grew its holdings in shares of Pacira Pharmaceuticals by 28,922.7% in the first quarter. BlackRock Inc. now owns 3,183,787 shares of the company’s stock valued at $145,180,000 after acquiring an additional 3,172,817 shares in the last quarter. 99.79% of the stock is owned by institutional investors.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Insider Buying and Selling by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.